Optimizing Meropenem in Highly Resistant Klebsiella pneumoniae Environments: Population Pharmacokinetics and Dosing Simulations in Critically Ill Patients

Antimicrobial Agents and Chemotherapy - Tập 66 Số 11 - 2022
Truong Anh Quan1, Dao Xuan Co2, Dinh Hoa Vu1, Hoang Anh Nguyen3,1, Thi Hong Gam3, Nhan Thang Tran3, Nhat Minh Tran1, Ngan Binh Vu4, Hong Nhung Pham5, Van Cuong Bui2, The Anh Trinh2, Quoc Tuan Dang2, Gia Binh Nguyen2, Jeffrey Lipman6,7,8, Menino Osbert Cotta8, Jason A. Roberts6,7,9,8
1National Drug Information and Adverse Drug Reaction Monitoring Centre, Hanoi University of Pharmacy, Hanoi, Vietnam
2Intensive Care Unit, Bach Mai Hospital, Hanoi, Vietnam
3Department of Pharmacy, Bach Mai Hospital, Hanoi, Vietnam
4Department of Analytical Chemistry and Toxicology, Hanoi University of Pharmacy, Hanoi, Vietnam
5Department of Microbiology, Bach Mai Hospital, Hanoi, Vietnam
6Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
7Division of Anaesthesiology Critical Care Emergency and Pain Medicine, Nîmes University Hospital, University of Montpellier, Nîmes, France
8University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia
9Pharmacy Department, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia

Tóm tắt

Critically ill patients are characterized by substantial pathophysiological changes that alter the pharmacokinetics (PK) of hydrophilic antibiotics, including carbapenems. Meropenem is a key antibiotic for multidrug-resistant Gram-negative bacilli, and such pathophysiological alterations can worsen treatment outcomes.

Từ khóa


Tài liệu tham khảo

10.1016/j.addr.2014.07.006

10.2165/00003088-200544100-00002

10.1016/j.medin.2015.07.009

Ventola CL. 2015. The antibiotic resistance crisis: part 1: causes and threats. Pharm Ther 40:277–283.

10.1099/mgen.0.000519

10.1016/j.jgar.2021.09.007

10.1586/eri.12.162

Clinical and Laboratory Standards Institute. 2022. CLSI M100-ED29: 2019 performance standards for antimicrobial susceptibility testing, 32nd ed. CLSI, Wayne, PA.

10.1093/infdis/jiw282

Tsereteli M Sidamonidze K Tsereteli D Malania L Vashakidze E. 2018. Epidemiology of carbapenem-resistant Klebsiella pneumoniae in intensive care units of multiprofile hospitals in Tbilisi Georgia p 164–168. Georgian Med News Tblisi Georgia.

10.1097/MD.0000000000004099

10.1186/s12879-017-2582-7

10.1016/j.ijantimicag.2017.08.019

10.1371/journal.pone.0201667

10.1016/j.clinthera.2018.07.001

10.1128/AAC.04166-14

10.1093/jac/dky434

Electronic Medicines Compendium. 2019. Summary of product characteristics: meronem IV 500 mg and 1g. https://www.medicines.org.uk/emc/medicine/11215#gref.

10.1097/FTD.0b013e31827d496c

10.1016/j.clinbiochem.2012.03.030

10.2165/00003088-199528040-00002

10.1097/CCM.0b013e3181961bff

10.1128/AAC.36.3.679

10.1016/j.ijantimicag.2019.06.016

10.1128/AAC.06389-11

10.1128/AAC.00794-17

10.3389/fphar.2021.781892

10.1093/jac/dkx330

10.1186/s40560-020-00442-7

10.1093/jac/dkv201

10.1128/CMR.00022-16

10.1093/jac/dkx209

10.1016/j.ijantimicag.2016.10.018

10.1128/AAC.00294-06

10.3390/antibiotics10111311

10.1128/AAC.49.12.4920-4927.2005

10.1093/jac/dkx001

10.1007/s00134-010-2105-0

Chi LD. 2017. Development of HPLC method for assay of imipenem and meropenem in plasma. Pharm J (Tap Duoc) 9:46. (In Vietnamese.)

US Food and Drug Administration. 2018. Bioanalytical method validation guidance for industry. FDA, Silver Spring, MD.

10.1097/FTD.0b013e31825c4ba6

Neely MN van Guilder MG Yamada WM Schumitzky A Jelliffe RW. 2015. An R package for parametric and non-parametric modeling and simulaton of pharmacokinetic and pharmacodynamic systems. http://www.lapk.org/software/Pmetrics/PM_User_manual.pdf.

10.1038/psp.2013.14

10.1086/344653

10.1093/cid/ciu027

10.1378/chest.11-1671

10.1093/jac/dki079

Thông tin
Thông tin xuất bản

Antimicrobial Agents and Chemotherapy

Tập 66 Số 11

Thông tin tác giả